RxDoctor Payments Data

Mitra Delshad

Family · Chico, CANPI 1659735637

Payments from drug & device makers

$8,733in general payments, 2019–2025

Across 316 payments — averaging $27.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Daiichi Sankyo Inc.$644
  • Bayer$464
  • AstraZeneca$452
  • Axsome Therapeutics, Inc.$425
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$8,733100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,733 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin310$233,037
OzempicSemaglutide182$170,338
FarxigaDapagliflozin Propanediol136$93,642
MounjaroTirzepatide64$67,802
KerendiaFinerenone61$43,709
EliquisApixaban48$34,944
MyrbetriqMirabegron50$28,879
Breo ElliptaFluticasone/Vilanterol51$20,482
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,662
TrulicityDulaglutide15$16,636
Nurtec OdtRimegepant Sulfate14$15,943
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl63$14,703
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$13,988
DapagliflozinDapagliflozin Propanediol15$12,091
TradjentaLinagliptin17$11,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,190$170,338182 claims
AstraZenecaFarxiga, Breztri Aerosphere$452$107,630158 claims
Lilly USA, LLCMounjaro, Trulicity$197$84,43879 claims
PfizerEliquis, Nurtec Odt, Paxlovid$111$52,31675 claims
BayerKerendia$464$43,70961 claims
GSKBreo Ellipta, Trelegy Ellipta$156$38,14478 claims
Astellas Pharma US IncMyrbetriq$59$28,87950 claims
AbbVieSynthroid$2,216$1,63919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Chico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →